Perspectives from the 2019 AACR Annual Meeting
April 10, 2019
Share:
Clarion joined over 20,000 attendees who gathered in Atlanta for the 2019 American Association for Cancer Research Annual Meeting to learn about cutting-edge advances in cancer biology and translational medicine. Below we summarize selected highlights of progress in immunotherapy, I-O biomarkers, cell therapy, targeted therapy, and new technologies that may enhance research and development in oncology.
Key takeaways
Immuno-oncology continues to make exciting progress, including:
- New immunotherapy drugs and drug combinations—including unprecedented early efficacy for pancreatic cancer and glioblastoma
- Exploratory I-O biomarkers and biomarker combinations
- Innovations in engineered cell therapy—including the most promising efficacy to date for solid-tumor CAR-T cell therapy
Targeted therapy advances include:
- Novel treatments to address acquired resistance
- Novel mechanisms for hard-to-treat cancers
Enabling technologies that may accelerate new product development include:
- New preclinical models for testing immunotherapy regimens
New digital systems for improving patient care and translational/clinical research
Click here to read the full perspectives for the 2019 AACR Annual Meeting